Aditi Jain: The relationship between key Immuno-Oncology clinical trial endpoints – ORR, PFS, and OS
Aditi Jain, Committee Member at shared on LinkedIn:
“Excited to share my latest first-author publication on the relationship between key Immuno-Oncology clinical trial endpoints: ORR, PFS, and OS.
In this study, we assess the validity of ORR as a surrogate for PFS and OS in the context of immunotherapy regimens. Our findings challenge the conventional expectation of a direct positive correlation between response rates and survival outcomes, raising important considerations for trial design and regulatory decision-making.
This project was particularly meaningful as it was my first time working extensively with biostatistics, and I am incredibly grateful for the support I received in navigating complex analytical concepts. A special thank you to Prof. Wei and Prof. Hajime at Harvard T.H. Chan School of Public Health for their guidance, and to my co-author Justin Stebbing for the opportunity and support.
I hope this paper contributes to a clearer understanding of how response rates relate to survival benefits and helps shape the design of future clinical trials and the approval process for new therapies.
Would love to hear any thoughts from those working in this space!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023